15

20

25

## WHAT IS CLAIMED IS:

- 1. A method to inhibit or prevent infectious agent transmission in a mammalian transplant recipient, comprising:
- introducing to donor swine cells a recombinant DNA comprising a promoter operably linked to a DNA segment encoding a protein comprising at least a portion of a polypeptide of the infectious agent that is present in the extracellular form of the agent so as to yield transformed swine cells, and
- b) introducing the transformed wine cells to the recipient.
  - 2. A method to inhibit or prevent infectious agent transmission in a mammalian transplant recipient,/comprising:
    - a) introducing to donor human blood cells a recombinant DNA comprising a promoter operably linked to a DNA segment encoding a protein comprising at least a portion of a polypeptide of the infectious agent that is present in the extracellular form of the agent so as to yield transformed human blood cells; and
    - b) introducing the transformed human blood cells to the recipient.
  - 3. A method to inhibit or prevent infectious agent transmission to a mammalian transplant recipient, comprising:
    - a) introducing to a donor organ a recombinant DNA comprising a promoter operably linked to a DNA segment encoding a protein comprising at least a portion of a polypeptide of the infectious agent that is present in the extracellular form of the agent so as to yield a transformed organ; and
    - b) introduçing the transformed organ to the recipient.
- 30 4. The method of claim 1, 2 or 3 wherein the DNA segment encodes a fusion protein comprising at least a portion of a polypeptide of the infectious agent that is present in the extracellular form of the agent and a degradative enzyme.

15.

30

<ul> <li>The method of claim 4 wherein the degradative enzyme protease.</li> <li>The method of claim 1, 2 or 3 wherein the infectious age</li> <li>The method of claim 6 wherein the polypeptide of the ir a viral capsid protein, viral glycoprotein or an accessory</li> </ul>	is a nuclease or
<ul> <li>6. The method of claim 1, 2 or 3 wherein the infectious age</li> <li>5</li> <li>7. The method of claim 6 wherein the polypeptide of the in</li> </ul>	
7. The method of claim 6 wherein the polypeptide of the in	
7. The method of claim 6 wherein the polypeptide of the in	ent is a virus.
a viral capsid protein, viral glycoprotein or an accessory	fectious agent is
	protein.
8. The method of claim 6 wherein the virus is a lentivirus,	retrovirus,
10 hepatitis virus or a herpesvirus.	
9. The method of claim 1 wherein the donor cells are embr	
blood cells, neuronal dells, liver cells, pancreatic cells, k	idney cells or
islet cells.	
15	
10. The method of claim 3 wherein the organ is a heart, live	r or kidney.
11. The method of claim 3 wherein the organ is a human or	pig organ.
	1 <b>6</b> :
20 12. The method of claim 4 wherein the DNA segment encode	
protein encoding a polypeptide of a pig endogenous retr	ovirus.
13. The method of claim 5 wherein the enzyme is barnase, s	taphylococcal
nuclease RNase H1, RNase T1, retroviral protease, RNa	ase III, RNaseL,
or a ribozyme.	•
14. The method of claim 7 wherein the polypeptide of the ir	fectious agent is
Vpr, Vpx, Vif or Nef.	

segment which comprises at least a portion of a pig endogenous

An isolated and purified nucleic acid molecule comprising a nucleic acid

retrovirus, wherein the nucleic acid segment hybridizes under hybridizing

15

25

conditions to SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:32.

- An isolated and purified polypeptide encoded by a nucleic acid molecule comprising a nucleic acid segment comprising SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:32.
- 17. A method to detect human tropic pig endogenous retroviruses, comprising:
  - a) contacting a mammalian sample suspected of being infected with a pig endogenous retrovirus with a probe comprising at least a portion of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:32 so as to form complexes; and
  - b) detecting or determining the presence of the complexes.
- 18. A method of using an isolated and purified nucleic acid molecule comprising the genome of a pig endogenous retrovirus comprising:

  20 introducing to a host cell a recombinant DNA molecule comprising a promoter operably linked to a DNA segment comprising SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:32 so as to yield a transformed host cell, and identifying the transformed host cell.
  - 19. The method of claim 1, 2, 3 or 18 wherein the recombinant DNA molecule further comprises transcriptional termination sequences 3' to the DNA segment.
- 30 20. A host cell, the genome of which is augmented with a recombinant DNA molecule comprising a promoter operably linked to a DNA segment encoding a fusion protein comprising at least a portion of a polypeptide of a pig endogenous retrovirus and a degradative enzyme.

32.

33.

34.

virus.

30

endogenous virus and a degradative enzyme.

WO 00/71726

21.

The method of claim 8 wherein the virus is human immunodeficiency

5

10

15

20

- 35. The method of claim 1, 2, 3 or 1/8 wherein the recombinant DNA is introduced to the recipient by infection with a recombinant virus.
- 36. A method to inhibit or prevent infectious agent transmission in a mammalian transplant recipient, comprising:
  - a) introducing to donor mammalian cells a recombinant DNA comprising a promoter operably linked to a DNA segment encoding a protein comprising at least a portion of a polypeptide of the infectious agent that is present in the extracellular form of the agent so as to yield transformed mammalian cells; and
  - b) introducing the transformed mammalian cells to the recipient.
- 37. A method to inhibit or prevent infectious agent transmission in a mammalian transplant recipient, comprising:
  - a) introducing to donor human cells a recombinant DNA encoding a protein comprising at least a portion of a polypeptide of the infectious agent that is present in the extracellular form of the agent so as to yield transformed human cells; and
  - b) introducing the transformed human cells to the recipient.
- 38. The method of claim 36 or 37 wherein the infectious agent is a virus.
- 39. The method of claim 38 wherein the polypeptide of the infectious agent is a viral capsid protein, viral glycoprotein or an accessory protein.